Original Research

Published on 06 Nov 2024

Concurrent chemoradiotherapy with S-1 versus platinum in the treatment of locoregionally advanced nasopharyngeal carcinoma: a multicenter, retrospective, propensity score-matched analysis

in Drugs Outcomes Research and Policies

Chenbin Bian
Zhuangzhuang Zheng
Jing Su
Sitong Chang
Huiyuan Yu
Jindian Bao
Qin Zhao
Xin Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1394754

Review

Published on 06 Nov 2024

Chemical adherence testing in the clinical management of hypertension: a scoping review

in Drugs Outcomes Research and Policies

Louise Rabbitt
James Curneen
Michael Conall Dennedy
Gerard J. Molloy

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1452464

296 views

Original Research

Published on 05 Nov 2024

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C

in Drugs Outcomes Research and Policies

Adina Turcu-Stiolica
Irina Paula Doica
Bogdan Silviu Ungureanu
Mihaela-Simona Subtirelu
Dan Nicolae Florescu
Razvan-Aurelian Turcu-Stiolica
Ion Rogoveanu
Dan-Ionut Gheonea

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1369166

246 views

Editorial

Published on 05 Nov 2024

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

in Drugs Outcomes Research and Policies

Atse H. Huisman
Denise van den Berg
Saco de Visser
Bettina Ryll
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1490853

247 views

Original Research

Published on 05 Nov 2024

Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China

in Drugs Outcomes Research and Policies

Kehui Meng
Heng Xiang
Meiyu Wu
Ouyang Xie
Andong Li
Chongqing Tan
Xiaomin Wan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1382342

219 views

Original Research

Accepted on 31 Oct 2024

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

in Drugs Outcomes Research and Policies

Szczepan Jakubowski
Przemysław Holko
Rafał Nowak
Marisa Warmuth
Marc Dooms
Outi Salminen
Lucas Cortial
Gisbert W. Selke
Christina Georgi
Einar Magnússon

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1498386

Correction

Published on 31 Oct 2024

Corrigendum: Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy

in Drugs Outcomes Research and Policies

Tanja Elnaz Hassanzadeh
Carina Hohmann
Carsten Culmsee

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1507320

Review

Published on 31 Oct 2024

Opioid-free strategies for patient-controlled intravenous postoperative analgesia: a review of recent studies

in Drugs Outcomes Research and Policies

Xin Luo
Pan-Guo Rao
Xing-Heng Lei
Wen-Wen Yang
Bao-Zhen Liao
Rui Guo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1454112

206 views

Original Research

Accepted on 28 Oct 2024

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases

in Drugs Outcomes Research and Policies

Qian Liu
Zhiwei Cui
Chao Deng
Chao Yang
Tao Shi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1485190

Original Research

Published on 28 Oct 2024

Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis

in Drugs Outcomes Research and Policies

Chun Xing Li
Cong Ying Li
Yu Qiao Wang
Hua Liu
Zhan Jiang Yang
Xian Zhang
Guan Chun Wang
Lei Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1462360

227 views

Original Research

Published on 25 Oct 2024

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

in Drugs Outcomes Research and Policies

Jiahong Zhong
Xihui Yu
Zhuomiao Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1486597

300 views

Brief Research Report

Published on 25 Oct 2024

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study

in Drugs Outcomes Research and Policies

Zhuoling Zheng
Yihong Zhao
Jingwen Xie
Min Gao
Yiting Wang
Xiaoyan Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1463026

287 views

Original Research

Accepted on 24 Oct 2024

Initial dosage optimization of quetiapine in schizophrenia patients: effect of fluvoxamine or duloxetine co-administration

in Drugs Outcomes Research and Policies

Xiao Chen
Yue Zhang
Di Yin
Ying-Wei Jin
Sumei He
Chen-Xu Liu
Cun Zhang
Dongdong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1496043

123 views

Original Research

Published on 24 Oct 2024

Pharmacist-led hospital intervention reduces unintentional patient-generated medication discrepancies after hospital discharge

in Drugs Outcomes Research and Policies

Maja Jošt
Lea Knez
Mitja Kos
Mojca Kerec Kos

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1483932

308 views

Original Research

Published on 23 Oct 2024

Transforming respiratory diseases management: a CMO-based hospital pharmaceutical care model

in Drugs Outcomes Research and Policies

Borja Zarate-Tamames
Noe Garin
Marta Calvin-Lamas
Sonia Jornet
Jose J. Martinez-Simon
Sara Garcia-Gil
Eva M. Garcia-Rebolledo
Ramon Morillo-Verdugo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1461473

389 views

Original Research

Published on 21 Oct 2024

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis

in Drugs Outcomes Research and Policies

Hongfu Cai
Ling Fang
Jingwen Lin
Zhiwei Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1476256

406 views

Navigation group

Articles

Concurrent chemoradiotherapy with S-1 versus platinum in the treatment of locoregionally advanced nasopharyngeal carcinoma: a multicenter, retrospective, propensity score-matched analysis

Chemical adherence testing in the clinical management of hypertension: a scoping review

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C

Editorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines

Evaluating nivolumab plus gemcitabine–cisplatin’s cost-effectiveness for aUC in China

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries

Corrigendum: Impact of a DSS-supported medication review on the safety of drug therapy and quality of life in patients with antithrombotic therapy

Opioid-free strategies for patient-controlled intravenous postoperative analgesia: a review of recent studies

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases

Sequential versus concomitant treatment of androgen receptor signaling inhibitors and docetaxel for metastatic hormone-sensitive prostate cancer: an network meta-analysis

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study

Initial dosage optimization of quetiapine in schizophrenia patients: effect of fluvoxamine or duloxetine co-administration

Pharmacist-led hospital intervention reduces unintentional patient-generated medication discrepancies after hospital discharge

Transforming respiratory diseases management: a CMO-based hospital pharmaceutical care model

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis